Translational Psychiatry (TP)
Journal Descriptions
Psychiatry has been held back by our limited translational pipeline. Nobel laureate Julius Axelrod's discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of most commonly prescribed types of antidepressants treatment. Likewise, dopamine receptor antagonists are widely used to treat schizophrenia. Pierre Deniker and Jean Delay conducted a clinical trial at the Sainte-Anne Hospital Center in Paris in which they treated 38 psychotic patients with daily injections of chlorpromazine, a dopamine receptor antagonist, without the use of other sedating agents. The response was dramatic; treatment with chlorpromazine went beyond simple sedation with patients showing improvements in thinking and emotional behavior. That was first reported in 1952. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients that will result in better outcomes than what is provided by existing approaches. Translational Psychiatry bridges this gap by focusing on papers that directly study psychiatric disorders and bring new discovery into clinical practice. In addition to this core mission of the journal, we may consider papers from all areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging, and epidemiology, that have potential to contribute to enhance the field of translational psychiatry more broadly. To maintain balance, such papers that do not directly address our core mission will be considered on a case-by-case basis, as a matter of editorial discretion, which can also be supported by advice gained during the peer review process.
Translational Psychiatry (TP) is :-
-
International, Peer-Reviewed, Open Access, Refereed, psychotic patients, psychiatric disorders, medical research, molecular biology, genetics, pharmacology, imaging, epidemiology , Online , Monthly Journal
- UGC Approved, ISSN Approved: P-ISSN E-ISSN: 2158-3188, Established: 2011, Impact Factor: 5.8
- Provides Crossref DOI
-
Indexed in: Scopus, WoS, DOAJ, PubMed
-
Not indexed in UGC CARE
